US approves Alzheimer's blood test for faster diagnosis

The U.S. has approved the first blood test for Alzheimer's disease, potentially enabling earlier and more effective patient care. This marks a significant advancement in diagnosing the disease. The test, developed by Fujirebio Diagnostics, measures amyloid beta and tau proteins in the blood, indicators of Alzheimer's. It is intended for patients already showing cognitive decline symptoms and requires confirmation with other clinical information. This blood test offers a simpler and faster alternative to current diagnostic methods like neuropsychological tests and spinal taps. It is expected to be available in Europe and potentially France next year.